Argos Therapeutics, Inc. Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
10/21/2009 8:44:15 AM
More...
|
Argos Therapeutics, Inc. to Present Positive Immune Response and Viral Load Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
10/13/2009 8:36:06 AM
More...
|
Argos Therapeutics, Inc. Publishes Research on the Immunosuppressive Properties of HIV
6/10/2009 8:52:31 AM
More...
|
Argos Therapeutics, Inc. Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the American Transplant Congress
6/1/2009 11:28:04 AM
More...
|
Argos Therapeutics, Inc. Announces Participation at BIO 2009 International Convention
5/13/2009 9:08:32 AM
More...
|
Argos Therapeutics, Inc. Presents Research Validating Feasibility and Safety of its Arcelis(TM) Personalized Immunotherapy Platform for HIV
4/24/2009 9:20:21 AM
More...
|
Argos Therapeutics, Inc. Presents Research on the Development and Evaluation of Immunotherapies for HIV
3/24/2009 9:02:22 AM
More...
|
Argos Therapeutics, Inc. Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the Canadian Society of Transplantation Congress
3/6/2009 10:36:59 AM
More...
|
Argos Therapeutics, Inc. Completes $35.2 Million Series C Financing
11/21/2008 10:42:16 AM
More...
|
Argos Therapeutics, Inc. to Discuss Personalized Dendritic Cell Immunotherapy Process at iSBTc Annual Meeting
10/31/2008 8:40:47 AM
More...
|
|